201 related articles for article (PubMed ID: 6692397)
21. Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells.
Craig RW; Frankfurt OS; Sakagami H; Takeda K; Bloch A
Cancer Res; 1984 Jun; 44(6):2421-9. PubMed ID: 6586286
[TBL] [Abstract][Full Text] [Related]
22. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
[TBL] [Abstract][Full Text] [Related]
23. Flow microfluorimetric analysis of sensitive and resistant leukemia L1210 following 1-beta-D-arabinofuranosylcytosine in vivo.
Alabaster O; Bunnag B
Cancer Res; 1976 Aug; 36(8):2744-9. PubMed ID: 1277184
[TBL] [Abstract][Full Text] [Related]
24. DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin.
Fram RJ; Kufe DW
Cancer Res; 1982 Oct; 42(10):4050-3. PubMed ID: 6809309
[TBL] [Abstract][Full Text] [Related]
25. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
[TBL] [Abstract][Full Text] [Related]
26. Cell kinetic studies of the effect of a combined therapy with 1-beta D-arabinofuranosylcytosine (Ara-C) and X-irradiation on the L1210 ascites tumour.
Fietkau R; Maurer-Schultze B
Cell Tissue Kinet; 1986 Jan; 19(1):93-107. PubMed ID: 3513957
[TBL] [Abstract][Full Text] [Related]
27. Enhanced radiation lethality in partially synchronized solid mouse tumors.
Todoroki T; Koike S; Tsunemoto H; Watanabe I
Cancer Res; 1982 Dec; 42(12):5231-5. PubMed ID: 7139626
[TBL] [Abstract][Full Text] [Related]
28. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
Matsushita T; Ryu EK; Hong CI; MacCoss M
Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
[TBL] [Abstract][Full Text] [Related]
29. Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy.
Moran RE; Straus MJ
Cancer Treat Rep; 1980 Jan; 64(1):81-6. PubMed ID: 7379059
[TBL] [Abstract][Full Text] [Related]
30. Detection of cytosine arabinoside resistant cells at low frequency using the bromodeoxyuridine/DNA assay.
Waldman FM; Dolbeare F; Gray JW
Cytometry; 1985 Nov; 6(6):657-62. PubMed ID: 4064845
[TBL] [Abstract][Full Text] [Related]
31. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM
Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
[TBL] [Abstract][Full Text] [Related]
32. Double labeling of S-phase murine cells with bromodeoxyuridine and a second DNA-specific probe.
Raza A; Spiridonidis C; Ucar K; Mayers G; Bankert R; Preisler HD
Cancer Res; 1985 May; 45(5):2283-7. PubMed ID: 3986772
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
Ho DH; Neil GL
Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
[TBL] [Abstract][Full Text] [Related]
34. Decreased cytotoxicity of 1-beta-D-arabinofuranosylcytosine in 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine in vitro.
Oredsson SM; Gray JW; Deen DF; Marton LJ
Cancer Res; 1983 Jun; 43(6):2541-4. PubMed ID: 6406046
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and cellular effects of didemnins A and B.
Crampton SL; Adams EG; Kuentzel SL; Li LH; Badiner G; Bhuyan BK
Cancer Res; 1984 May; 44(5):1796-801. PubMed ID: 6713383
[TBL] [Abstract][Full Text] [Related]
36. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells.
Roberts D; Peck C
Cancer Res; 1981 Feb; 41(2):505-10. PubMed ID: 7448798
[TBL] [Abstract][Full Text] [Related]
37. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
38. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
Cass CE; Selner M; Phillips JR
Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
[TBL] [Abstract][Full Text] [Related]
39. Effects of the tricyclic nucleoside 6-amino-4-methyl-8-(beta-D-ribofuranosyl)- pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine on the viability and cell cycle distribution of L1210 cells in vitro.
Wotring LL; Passiatore JE; Roti Roti JL; Hudson JL; Townsend LB
Cancer Res; 1985 Dec; 45(12 Pt 1):6355-61. PubMed ID: 4063986
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.
LePage GA; Worth LS; Kimball AP
Cancer Res; 1976 Apr; 36(4):1481-5. PubMed ID: 946595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
